[1]
|
Engevik, A.C., Kaji, I. and Goldenring, J.R. (2020) The Physiology of the Gastric Parietal Cell. Physiological Reviews, 100, 573-602. https://doi.org/10.1152/physrev.00016.2019
|
[2]
|
Shin, J.M., Munson, K. and Sachs, G. (2011) Gastric H+, K+-ATPase. Comprehensive Physiology, 1, 2141-2153.
https://doi.org/10.1002/cphy.c110010
|
[3]
|
Nugent, C.C., Falkson, S.R. and Terrell, J.M. (2022) H2 Blockers. StatPearls. Treasure Island.
|
[4]
|
张石革, 宗怡. 组胺H2受体拮抗剂的进展与合理应用[J]. 中国全科医学, 2002, 5(11): 913-916.
|
[5]
|
Brett, M.F. (2018) Management of Gastroesophageal Reflux Disease in Adults: A Pharmacist’s Perspective. Integrated Pharmacy Research and Practice, 7, 41-52. https://doi.org/10.2147/IPRP.S142932
|
[6]
|
赵斌, 解学超, 王振华, 魏开惠. 组胺H2受体拮抗剂不良反应的流行病学特点研究[J]. 中国医院药学杂志, 2014, 34(8): 675-678.
|
[7]
|
Histamine Type-2 Receptor Antagonists (H2 Blockers). In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethes-da.
|
[8]
|
Martínez, C., Albet, C., Agúndez, J.A., Herrero, E., Carrillo, J.A., Márquez, M., Benítez, J. and Ortiz, J.A. (1999) Comparative in Vitro and in Vivo Inhibition of Cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-Receptor Antagonists. Clinical Pharmacology & Therapeutics, 65, 369-376. https://doi.org/10.1016/S0009-9236(99)70129-3
|
[9]
|
El Rouby, N., Lima, J.J. and Johnson, J.A. (2018) Proton Pump Inhibitors: from CYP2C19 Pharmacogenetics to Precision Medicine. Expert Opinion on Drug Metabolism & Toxicology, 14, 447-460.
https://doi.org/10.1080/17425255.2018.1461835
|
[10]
|
张培培, 王永庆, 龚晓健. 质子泵抑制剂研究新进展[J]. 药学进展, 2011, 35(11): 487-495.
|
[11]
|
Shin, J.M., Munson, K, Vagin, O. and Sachs, G. (2011) Erratum: The Gastric HK-ATPase: Structure, Function, and Inhibition. Pflügers Archiv—European Journal of Physiology, 461, 399-399.
https://doi.org/10.1007/s00424-010-0907-0
|
[12]
|
Salas, M., Ward, A. and Caro, J. (2002) Are Proton Pump Inhib-itors the First Choice for Acute Treatment of Gastric Ulcers? A Meta Analysis of Randomized Clinical Trials. BMC Gastroenterology, 2, Article No. 17.
https://doi.org/10.1186/1471-230X-2-17
|
[13]
|
van Pinxteren, B., Numans, M.E., Bonis, P.A. and Lau, J. (2003) Short-Term Treatment with Proton Pump Inhibitors, H2-Receptor Antagonists and Prokinetics for Gastro-Oesophageal Reflux Disease-Like Symptoms and Endoscopy Negative Reflux Disease. Cochrane Database of Systematic Reviews, 5, Article ID: CD002095.
https://doi.org/10.1002/14651858.CD002095.pub2
|
[14]
|
Zhang, Y.-S., Li, Q., He, B.-S., Liu, R. and Li, Z.-J. (2015) Proton Pump Inhibitors Therapy vs H2 Receptor Antagonists Therapy for Upper Gastrointestinal Bleeding after Endoscopy: A Meta-Analysis. World Journal of Gastroenterology, 21, 6341-6351. https://doi.org/10.3748/wjg.v21.i20.6341
|
[15]
|
袁培杰, 李夏平, 李乐谦, 刘伟, 黄梅芳, 熊婧. 高剂量二联疗法与经典四联疗法根除幽门螺杆菌的疗效对比[J]. 现代消化及介入诊疗, 2021, 26(6): 681-684.
|
[16]
|
张丽君, 吕栋. 雷贝拉唑三联及四联疗法根除Hp感染消化性溃疡[J]. 中国继续医学教育, 2019, 11(28): 139-141.
|
[17]
|
Shin, J.M. and Sachs, G. (2008) Pharmacology of Proton Pump Inhibitors. Current Gastroenterology Reports, 10, Article No. 528. https://doi.org/10.1007/s11894-008-0098-4
|
[18]
|
王世鑫. 抑酸剂的现状与展望[J]. 中国消化内镜, 2008, 2(4): 41-46.
|
[19]
|
单清, 孙安修. 质子泵抑制剂预防性应用专家共识(2018) [J]. 中国医师杂志, 2018, 20(12): 1775-1781.
|
[20]
|
王焱, 刘英, 李芳, 张国领. 质子泵抑制剂的临床应用研究进展[J]. 中华保健医学杂志, 2021, 23(4): 415-416, 419.
https://doi.org/10.3969/j.issn.1674-3245.2021.04.031
|
[21]
|
Bavishi, C. and DuPont, H.L. (2011) Systematic Re-view: The Use of Proton Pump Inhibitors and Increased Susceptibility to Enteric Infection. Alimentary Pharmacology & Therapeutics, 34, 1269-1281.
https://doi.org/10.1111/j.1365-2036.2011.04874.x
|
[22]
|
Mcdonald, E.G., Milligan, J., Frenette, C. and Lee, T.C. (2015) Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection. JAMA Internal Medicine, 175, 784-791.
https://doi.org/10.1001/jamainternmed.2015.42
|
[23]
|
Yang, Y.X, Lewis, J.D., Epstein, S. and Metz, D.C. (2006) Long-Term Proton Pump Inhibitor Therapy and Risk of Hip Fracture. JAMA: The Journal of the American Medical Association, 296, 2947-2953.
https://doi.org/10.1001/jama.296.24.2947
|
[24]
|
Echizen, H. (2016) The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical Pharmacokinetics, 55, 409-418.
https://doi.org/10.1007/s40262-015-0326-7
|
[25]
|
Inatomi, N., Matsukawa, J., Sakurai, Y. and Otake, K. (2016) Potassium-Competitive Acid Blockers: Advanced Therapeutic Option for Acid-Related Diseases. Pharmacology & Therapeutics, 168, 12-22.
https://doi.org/10.1016/j.pharmthera.2016.08.001
|
[26]
|
Sakurai, Y., Nishimura, A., Kennedy, G., et al. (2015) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/Non-Japanese Subjects. Clinical and Translational Gastroenterology, 6, e94. https://doi.org/10.1038/ctg.2015.18
|
[27]
|
Herszényi, L., Bakucz, T., Barabás, L. and Tulassay, Z. (2019) Pharma-cological Approach to Gastric Acid Suppression: Past, Present, and Future. Digestive Diseases, 38, 104-111. https://doi.org/10.1159/000505204
|
[28]
|
Ashida, K., Sakurai, Y., Hori, T., et al. (2016) Randomised Clinical Trial: Vonoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Lansoprazole for the Healing of Erosive Oesophagitis. Alimentary Pharmacology & Therapeutics, 43, 240-251. https://doi.org/10.1111/apt.13461
|
[29]
|
Kawai, T., Ashida, K., Mizokami, Y., et al. (2014) Tu1055 TAK-438 versus Lansoprazole 15 mg for Secondary Prevention of Peptic Ulcers Associated with Low-Dose Aspirin Therapy: Results of a Phase 3 Trial. Gastroenterology, 14, S-739. https://doi.org/10.1016/S0016-5085(14)62678-0
|
[30]
|
Murakami, K., Sakurai, Y., Shiino, M., et al. (2016) Vonoprazan, a Novel Potassium-Competitive Acid Blocker, as a Component of First-Line and Second-Line Triple Therapy for Helicobacter pylori Eradication: A Phase III, Randomised, Double-Blind Study. Gut, 65, 1439-1446. https://doi.org/10.1136/gutjnl-2015-311304
|
[31]
|
Kiyotoki, S., Nishikawa, J. and Sakaida, I. (2020) Efficacy of Vonoprazan for Helicobacter pylori Eradication. Internal Medicine, 59, 153-161. https://doi.org/10.2169/internalmedicine.2521-18
|
[32]
|
Tanabe, H., Yoshino, K., Ando, K., et al. (2018) Vonoprazan-Based Triple Therapy Is Non-Inferior to Susceptibility-Guided Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication. Annals of Clinical Microbiology and Antimicrobials, 17, Article No. 29. https://doi.org/10.1186/s12941-018-0281-x
|
[33]
|
Miftahussurur, M., Putra, B.P. and Yamaoka, Y. (2020) The Po-tential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals, 13, Article No. 276. https://doi.org/10.3390/ph13100276
|
[34]
|
Kambara, H., Hosohata, K., Nakatsuji, T., et al. (2020) Safety Profile of Vonoprazan Compared with Proton Pump Inhibitors: Insight from a Pharmacovigilance Study. Die Pharmazie—An International Journal of Pharmaceutical Sciences, 75, 527-530.
|